Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 10/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | GCKR | Q14397 | 1/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089206 | 0.88 | GCK (0.80) | GCKGCKRHSD11B1 | |
| SCHEMBL17333 | 0.86 | GCK (1.00) | GCKPOLBTHRBGCKR | |
| SCHEMBL12089841 | 0.84 | GCK (0.59) | GCKPOLBTHRBGCKRHSD11B1 | |
| SCHEMBL12089451 | 0.84 | GCK (0.73) | GCKGCKRHSD11B1MEN1KMT2A | |
| SCHEMBL12088782 | 0.81 | GCK (0.72) | GCKPOLBHSD11B1MEN1KMT2A | |
| SCHEMBL12089376 | 0.80 | GCK (0.54) | GCKPOLBTHRBGCKRHSD11B1 | |
| SCHEMBL12089719 | 0.78 | GCK (0.57) | GCKPOLBGCKRHSD11B1MEN1 | |
| SCHEMBL12089602 | 0.78 | GCK (0.76) | GCKPOLBTHRBGCKRHSD11B1 | |
| SCHEMBL15834 | 0.78 | GCK (1.00) | GCKGCKR | |
| SCHEMBL30956 | 0.78 | GCK (1.00) | GCKGCKR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GCK 2/4885POLB 4613/4885THRB 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.